Project Grant R01AA031662
Award Date
9/23/24
Completion Date
6/30/29
Dollars Obligated
$731K
Federal Agency
National Institute on Alcohol Abuse and Alcoholism
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11794, USA
Similar Awards
This federal Project Grant award of $581,869 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the CFDA 93.273 Alcohol Research Programs, will fund a human neuroscience study to investigate the role of glucocorticoid receptor (GR) antagonism in alcohol use disorder (AUD). The study will evaluate the effects of a selective GR antagonist, PT150, on behavioral, neuroendocrinological, and physiological responses to stress and alcohol in 34 participants. The research aims...
This federal Project Grant award of $1,135,243 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support research to investigate changes in neural mechanisms associated with cognitive reappraisal and alcohol cue reactivity during early abstinence from alcohol use disorder (AUD) treatment. The research, conducted by the University of Colorado-Denver and involving sub-awards to Emory University and the University of Denver,...
This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...
This federal Project Grant award of $710,992, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), supports a longitudinal study to understand the trajectory, mechanisms, and impacts of changes in emotion processing deficits during early alcohol use disorder (AUD) recovery. The University of Florida, the primary awardee, will recruit recently abstinent individuals in residential AUD treatment and a matched community control...
The federal Project Grant award R00AA030665 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program. The $249,001 award, effective May 1, 2025, supports a study entitled "Study Aimed at Increasing Alcohol Abstinence (DEDICATE)" to be conducted by the University of Illinois. The key objectives of this project are to (1) test the efficacy of combining contingency management (CM) with...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,373,036 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University. The overarching goal of this 5-year research project (Sep 2024 - Aug 2029) is to enhance the understanding and prediction of heavy drinking episodes during initial recovery from alcohol use disorder (AUD). The project aims to leverage wearable biosensor technology and artificial intelligence to develop real-time predictive...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, is funding a Phase II clinical trial to evaluate the use of the drug tirzepatide (Zepbound) in adults with co-occurring alcohol use disorder and overweight/obesity. The $211,247 award supports an 8-week double-blind study at the University of Southern California to assess the effects of tirzepatide on alcohol use, weight,...
This $366,406 Project Grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Yale University. The grant will be used to develop two novel human laboratory models to screen potential medications for Alcohol Use Disorder (AUD). The first model will assess a medication's ability to increase abstinence and reduce heavy drinking, which align with key FDA endpoints for AUD medication approval. The second model will...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $481,428 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the Moses-Weitzman Health System, Inc. on September 20, 2024. The project, titled "Translating Research into Practice on Alcohol and Polysubstance Use Disorders by Educating the Interprofessional Primary Care Team," aims to improve the capacity of primary care providers in federally qualified health centers and other safety net settings to...
This Project Grant award of $1,227,554.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a prospective examination of transdermal alcohol concentration (TAC) features as predictors of alcohol-related consequences and alcohol use disorders (AUDs) among 500 young adults. The research aims to: 1) examine TAC features as predictors of alcohol-related consequences, relative to ecological momentary assessment (EMA)...